Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Appl Toxicol ; 39(8): 1192-1207, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31134659

RESUMO

Marketed (bosentan, ambrisentan) and discontinued (sitaxsentan, CI-1034) endothelin receptor antagonists were examined in the human micropatterned hepatocyte co-culture (MPCC) model HepatoPac® . Differences across hepatocellular health (cellular adenosine triphosphate/glutathione content), function (urea production/albumin secretion) and taurocholic acid transport (biliary clearance/excretion index) were compared using amiodarone and ciclosporin A as positive controls. Ambrisentan had the weakest potency in all six endpoints, while sitaxsentan, bosentan and CI-1034 had more potent effects on hepatobiliary transport than health/function endpoints. Normalization to clinical Cmax gave the following relative rank order of safety based on margins for each endpoint: ambrisentan ≥ CI-1034 ~ bosentan > sitaxsentan. These data suggested impaired hepatobiliary disposition might contribute to a more prominent role in liver injury associated within sensitive human populations exposed to these compounds than direct hepatocellular toxicity. Rat, dog and monkey MPCCs also showed greater sensitivity potential to disrupted hepatobiliary disposition compared with hepatocellular health/functional endpoints. Drug metabolism competency was exhibited across all species. In vivo, rats and dogs appear more resistant to transaminase elevations and/or histological evidence of liver injury caused by these mechanisms even at exceedingly high systemic exposures relative to sensitive humans. Rats and dogs are resistant to hepatobiliary toxicants due to physiological differences in bile composition/handling. Although traditional animal testing provides adequate safety coverage for advancement of novel pharmaceuticals into clinical trials, supplemental assays employing human MPCCs may strengthen weight-of-evidence predictions for sensitive human populations. Proving the predictive value of this single impact assessment model in advance of clinical trial information for human liver injury risk is needed across more pharmaceuticals.


Assuntos
Antagonistas dos Receptores de Endotelina/toxicidade , Hepatócitos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Modelos Biológicos , Receptores de Endotelina/metabolismo , Ácido Taurocólico/metabolismo , Animais , Transporte Biológico , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Técnicas de Cocultura , Cães , Antagonistas dos Receptores de Endotelina/metabolismo , Hepatócitos/metabolismo , Hepatócitos/patologia , Humanos , Fígado/metabolismo , Macaca fascicularis , Ratos , Ratos Sprague-Dawley , Especificidade da Espécie
2.
Rapid Commun Mass Spectrom ; 29(22): 2175-83, 2015 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-26467230

RESUMO

RATIONALE: The covalent modification of proteins by toxicants, new chemical entities or drug molecules, either by metabolic activation or the presence of inherently reactive functional groups, is commonly implicated in organ toxicity and idiosyncratic reactions. In efforts to better prosecute protein modifications, we investigated a tag-free technique capable of detecting protein-small molecule adducts based solely on the collision-induced dissociation (CID) of the protein-small molecule complex. Detection of proteins using unique CID small molecule (SM) product ions would mitigate common issues associated with tagging technologies (e.g., altered reactivity/affinity of the protein-SM complex). METHODS: A Waters SYNAPT G2 mass spectrometer (MS) was operated in MS(e) mode with appropriate collision energy conditions during the MS(2) acquisition for fragmentation of protein-small molecule adducts to generate characteristic small molecule product ions. RESULTS: Ibrutinib, an acrylamide-containing small molecule drug, was shown to form adducts with rat serum albumin in ex vivo experiments and these adducts were detected by relying solely on the CID product ions generated from ibrutinib. Additionally, ibrutinib produced three CID product ions, one of which was a selective protein-ibrutinib fragment ion not produced by the compound alone. CONCLUSIONS: Herein we describe a tag-free mass spectral detection technique for protein-small molecule conjugates that relies on the unique product ion fragmentation profile of the small molecule. This technique allows the detection of macromolecular ions containing the adducted small molecule from complex protein matrices through mass range selection for the unique product ions in the CID spectra.


Assuntos
Íons/química , Espectrometria de Massas/métodos , Preparações Farmacêuticas/química , Proteínas/química , Adenina/análogos & derivados , Animais , Cromatografia Líquida de Alta Pressão , Humanos , Íons/análise , Íons/metabolismo , Modelos Químicos , Preparações Farmacêuticas/metabolismo , Piperidinas , Proteínas/análise , Proteínas/metabolismo , Pirazóis , Pirimidinas , Ratos
3.
Bioorg Med Chem Lett ; 22(8): 2856-60, 2012 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-22429467

RESUMO

Aldehyde oxidase (AO) is a molybdenum-containing enzyme distributed throughout the animal kingdom and capable of metabolising a wide range of aldehydes and N-heterocyclic compounds. Although metabolism by this enzyme in man is recognised to have significant clinical impact where human AO activity was not predicted by screening in preclinical species, there is very little reported literature offering real examples where drug discoverers have successfully designed away from AO oxidation. This article reports on some strategies adopted in the Pfizer TLR7 agonist programme to successfully switch off AO metabolism that was seen principally in the rat.


Assuntos
Aldeído Oxidase/metabolismo , Piridinas/síntese química , Aldeído Oxidase/antagonistas & inibidores , Aldeído Oxidase/química , Animais , Células Cultivadas , Química Farmacêutica , Citosol/enzimologia , Cães , Estabilidade de Medicamentos , Humanos , Masculino , Piridinas/química , Ratos , Relação Estrutura-Atividade , Receptor 7 Toll-Like/agonistas
4.
J Agric Food Chem ; 52(8): 2179-91, 2004 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-15080618

RESUMO

Tulathromycin is a novel member of the triamilide class of antibiotics that was developed as a safe and effective single-dose treatment of bovine and porcine respiratory disease. An accurate and precise analytical method was developed for the extraction and measurement of tulathromycin in livestock plasma and lung homogenates. Analytes were solid-phase extracted onto a weak cation exchanger after aqueous dilution of samples and addition of heptadeutero-tulathromycin as an internal standard. Following HPLC with a narrow bore C8 column, quantitative detection of tulathromycin was accomplished by monitoring the transition of a doubly charged precursor ion to a singly charged product ion by tandem mass spectrometry using a triple quadrupole mass spectrometer. Procedures were validated for a dynamic range of 0.1 to 25 ng on column. Observed accuracies were between 90 and 110% of nominal and precision (RSD) varying 7% or less. Response and stability experiments showed that deuterated tulathromycin did not parallel the chemical behavior of tulathromycin. Applicability of the method to livestock studies was tested with plasma and lung samples from cattle and swine dosed with tulathromycin at multiple doses. The results demonstrated that the analytical method performed well in a range of sample concentrations spanning over 3 orders of magnitude and provided dose-exposure relationships for cattle and swine.


Assuntos
Antibacterianos/análise , Bovinos/metabolismo , Dissacarídeos/análise , Compostos Heterocíclicos/análise , Pulmão/química , Suínos/metabolismo , Animais , Antibacterianos/sangue , Bovinos/sangue , Cromatografia Líquida de Alta Pressão , Dissacarídeos/sangue , Dissacarídeos/farmacocinética , Relação Dose-Resposta a Droga , Estabilidade de Medicamentos , Compostos Heterocíclicos/sangue , Compostos Heterocíclicos/farmacocinética , Espectrometria de Massas , Controle de Qualidade , Sensibilidade e Especificidade , Suínos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA